SYM Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Symbotic Inc. (SYM) Investors that a Securities Fraud Class Action Lawsuit Has Been Filed
- 80
Radnor, Pennsylvania--(Newsfile Corp. - December 29, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Symbotic Inc. ("Symbotic") (NASDAQ: SYM) on behalf of those who purchased or otherwise acquired Symbotic securities between February 8, 2024, and November 26, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is February 3, 2025.
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Symbotic losses, you may CLICK HERE or copy and paste this link into your browser: https://www.ktmc.com/new-cases/symbotic-inc-2?utm_source=PR&utm_medium=link&utm_campaign=sym&mktm=r
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].
DEFENDANTS' ALLEGED MISCONDUCT:
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Symbotic improperly accelerated its revenue recognition in its second and third quarter 2024 financial statements; (2) the company had a material weakness in its internal controls over financial reporting; and (3) as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
THE LEAD PLAINTIFF PROCESS:
Symbotic investors may, no later than February 3, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Symbotic investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE OR COPY AND PASTE THIS LINK INTO YOUR BROWSER: https://www.ktmc.com/new-cases/symbotic-inc-2?utm_source=PR&utm_medium=link&utm_campaign=sym&mktm=r
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235387
Newsfile Corp. is a press release service for companies of all sizes. With a distribution of over 6,000 media and financial databases, Newsfile delivers press releases to a global audience.
- Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
- Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
- ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Joint Stock Company Kaspi.kz Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - KSPI
- ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
- ASML Deadline: ASML Investors with Losses in Excess of $100K Have Opportunity to Lead ASML Holding N.V. Securities Fraud Lawsuit
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA